Phase III study of surgery (S) versus definitive concurrent chemoradiotherapy boost (def ccCRTx-BOx) in patients (pts) with operable (OP+) stage IIIA(N2)/selected IIIb (sel IIIB) non-small cell lung cancer (NSCLC) following induction (IND) chemotherapy (CTx) and concurrent CRTx (ESPATUE).

• DOI: 10.1200/jco.2014.32.15_suppl.7510
• Publication Date: 2019-01-03T22:35:36Z
• Authors: Wilfried Ernst Er...; Thomas Christoph ...; Christoph Pöttgen; Godehard Friedel; Stefanie Veit; Vanessa Heinrich; Stefan Welter; Werner Spengler; Martin Kimmich; Berthold Fischer; Heinz Schmidberger; Eleni Gkika; Sebastian Cordes; Rodrigo Hepp; Diana Luetke-Brin...; Nils Lehmann; Martin H. Schuler; Karl-Heinz Jöckel; Georgios Stamatis; Martin Stuschke
• Keywords: 03 medical and health sciences; 0302 clinical medicine; Medizin; 3. Good health

7510 Background: Def ccCRTx or ccCRTx + S are accepted therapies (Tx) for OP+ stage IIIA(N2) NSCLC (Albain 2009). Our multicenter phase-II showed efficacy of CTx + ccCRTx + S in IIIA(N2) / sel IIIB...